<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951288</url>
  </required_header>
  <id_info>
    <org_study_id>SafAMD</org_study_id>
    <nct_id>NCT00951288</nct_id>
  </id_info>
  <brief_title>Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration</brief_title>
  <acronym>safAMD</acronym>
  <official_title>Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot interventional study whose aim is to determine the effect of a dietary
      supplementation with a Crocus Sativus extract, Saffron, on macular cone-mediated function in
      patients with early age-related macular degeneration (AMD). Pre-clinical evidence ( Maccarone
      R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure
      to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1254-61.)
      indicates the potential effectiveness of Saffron as a retinal neuroprotectant in animal
      models of retinal degenerative disorders.The macular function will be tested by visual acuity
      and macular cone-mediated electroretinogram (focal electroretinogram, FERG) according to a
      standardized technique (see citations).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A group of 30 AMD patients with typical lesions (drusen and/or retinal pigment epithelial
      defects) and relatively preserved central retinal function and visual acuity will be
      enrolled. AMD patients will be randomly divided into two groups: 1. placebo group [n = 15),
      taking for three months an oral placebo; 2. Saffron group (n = 15), taking Saffron oral
      treatment (20 mg/day) for three months. After three months of placebo or Saffron
      supplementation, patients will be tested with standard ophthalmic examination and FERGs.
      Then, placebo with Saffron and vice-versa will be changed to the same patients in a
      cross-over design. After a further three month period of placebo or study drug
      supplementation, patients will undergo again a standard ophthalmic examination, and FERG.
      Throughout the study, both patients and experimenters will be masked as to the identity of
      pills (i.e. whether placebo or study drug), whose identification key number will be kept in a
      sealed envelope that will be opened only at the completion of the study. Therapeutic
      compliance will be tested by careful questioning, either at two weeks of treatment (by
      telephone interview) or at the end of the treatment period, as well as by pill count. Main
      outcome measures of the study will be FERG amplitude and phase.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Focal Electroretinogram Amplitude and Phase</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Saffron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crocus Sativus extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saffron</intervention_name>
    <description>Saffron 20 mg/day supplementation</description>
    <arm_group_label>Saffron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 55 yrs

          -  Diagnosis of Early, non exudative AMD

          -  Visual acuity of 20/40 or better

        Exclusion Criteria:

          -  Concomitant ocular or systemic disorders which may affect macular function

          -  Drugs that may affect macular function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedetto Falsini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico A. Gemelli, Institute of Ophthalmology</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1254-61. doi: 10.1167/iovs.07-0438.</citation>
    <PMID>18326756</PMID>
  </reference>
  <reference>
    <citation>Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P. Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology. 2003 Jan;110(1):51-60; discussion 61.</citation>
    <PMID>12511345</PMID>
  </reference>
  <reference>
    <citation>Falsini B, Fadda A, Iarossi G, Piccardi M, Canu D, Minnella A, Serrao S, Scullica L. Retinal sensitivity to flicker modulation: reduced by early age-related maculopathy. Invest Ophthalmol Vis Sci. 2000 May;41(6):1498-506.</citation>
    <PMID>10798669</PMID>
  </reference>
  <results_reference>
    <citation>Falsini B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, Balestrazzi E, Maccarone R, Bisti S. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6118-24. doi: 10.1167/iovs.09-4995. Epub 2010 Aug 4.</citation>
    <PMID>20688744</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>July 31, 2015</last_update_submitted>
  <last_update_submitted_qc>July 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Benedetto Falsini</investigator_full_name>
    <investigator_title>Associate Professor, Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Retinal Function</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

